Penumbra has announced the completion of enrollment in the STORM-PE clinical trial.
The pivotal, prospective, multicenter randomized controlled trial enrolled 100 patients to evaluate computer assisted vacuum thrombectomy (CAVT) using Penumbra’s Lightning Flash plus anticoagulation versus anticoagulation alone for the treatment of acute intermediate-high risk pulmonary embolism (PE).
Conducted in partnership with The PERT Consortium, a multidisciplinary group dedicated to improving the care of patients with PE, the trial aims to provide high-quality evidence on the role of CAVT in improving right heart function and clinical outcomes in this critically ill patient population.
The Lightning Flash catheter is made with MaxID hypotube technology, allowing an inner diameter similar to large-bore catheters while maintaining a lower profile and a soft, atraumatic tip design. They are designed to help remove blood clots with speed, safety and simplicity, allowing physicians to better navigate the body’s complex anatomy and deliver high power aspiration for clot removal, the company state.
